Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor

May 25 th , 2023 at 11:00 AM ET (Virtual Event) WALTHAM, Mass. & MONTREAL — May 1, 2023 — (BUSINESS WIRE) — Ventus Therapeutics , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that it will host its inaugural Program Spotlight on VENT-03 on May 25 th , 2023 at 11:00 AM ET. The virtual event will feature VENT-03, a first-in-class cGAS inhibitor in development for lupus and other inflammatory disorders. cGAS, a highly sought-after target, is an innate immune sensor of nucleic acids that, when aberrantly activated, leads to auto-inflammation and tissue damage. The pathway has been clinically validated in systemic lupus erythematosus (SLE) and is implicated in a wide range of immunological and neuroinflammatory conditions. Ventus has demonstrated proof-of-mechanism with its portfolio of cGAS inhibitors in multiple disease models. Despite significant efforts across the industry over the past decade, VENT-03 will be the first cGAS inhibitor to advance to the clinic, demonstrating Ventus’ ability to drug a target that has been undruggable to date and has the potential to significantly improve treatment options for patients. As part of the event, Ventus scientists, together with Dr. Victoria Werth, Professor of Dermatology and Medicine at Penn Medicine, will discuss the biology of the cGAS pathway and its importance in immunology. They will also review the current treatment landscape and the potential of VENT-03 as an effective treatment for SLE and present the clinical development plan for VENT-03, including an overview of Ventus’ differentiated translation to the clinic. A live question and answer session will follow. To register for the event, please click here . About cGAS cGAS is an intracellular pattern recognition receptor that is activated after binding to double-stranded DNA (dsDNA) in the cytoplasm. dsDNA in the cytoplasm is generally associated with cellular dysfunction, as seen in multiple diseases such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and dermatomyositis (DM). cGAS activation leads to cGAMP formation, activation of STING and downstream expression of type I interferons such as IFN-α, -ß and -κ, leading to pronounced inflammation and tissue damage. This pathway also leads to the expression of several other proinflammatory cytokines such as CXCL10. Genetic mutations that lead to the aberrant activation of cGAS/STING in humans are known to cause severe infant onset Aicardi-Goutières Syndrome (AGS) and genetic forms of chilblain lupus, demonstrating the relevance of the pathway in human diseases. Given that the pathophysiology and presentation of these genetic diseases have significant similarities with idiopathic complex diseases such as SLE, CLE, and DM, these diseases represent highly compelling opportunities for treatment with a cGAS inhibitor. About Ventus Therapeutics Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation, and neurology. The Company’s proprietary drug discovery platform, ReSOLVE TM , gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated therapies at a fast pace. Ventus’ first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor. These programs exemplify Ventus’ unique discovery capabilities and focus on first- and best-in-class programs for multi-indication immunology targets with franchise potential. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects, including, but not limited to, statements related to the anticipated benefits of Ventus’ business strategy, pipeline programs, drug discovery platform, and financial position. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to the risks and uncertainties inherent in Ventus’ business, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE TM platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers, manufacturers, and CROs; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Media Contact Alexis Feinberg ICR Westwicke 203-939-2225 [email protected] © 2026 Ventus Therapeutics. All Rights Reserved. Explore About Pipeline Platform Patients News & Events Careers Viewpoints Contact For general inquiries - [email protected] For medical inquiries - [email protected] USA 100 Beaver St, Suite 201 Waltham, Massachusetts 02453 Canada 4800, rue Lévy # 110 Saint-Laurent, H4R 2P1, QC, Canada Follow Us Legal Privacy Policy Cookie Policy click click MENU About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Viewpoints À propos Aperçu Direction Conseil d’administration Fondateurs Consultants Investisseurs Filiere de Developpement Filiere de Developpement VENT-03 VENT-02 VENT-04 Plateforme Essais cliniques Actualités et événements Dernières Nouvelles événements Dans les médias Emplois Aperçu Postes Vacants Points de vue We are using cookies to give you the best experience on our website. To find out more about the information we collect, please review our Privacy Policy . You can find out more about which cookies we are using or switch them off in settings . Nous utilisons des témoins pour vous offrir la meilleure expérience possible sur notre site Web. Pour en savoir plus sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Vous y trouverez de plus amples renseignements sur les témoins que nous utilisons, ou vous pouvez les désactiver dans les paramètres . Accept / Accepter Settings / Paramètres Close GDPR Cookie Settings Privacy Overview / Généralités sur la confidentialité Strictly Necessary Cookies / Témoins strictement nécessaires 3rd Party Cookies / Témoins tiers Powered by GDPR Cookie Compliance Privacy Overview / Généralités sur la confidentialité This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. To find out more about the information we collect, please review our Privacy Policy . Nous utilisons des témoins afin de vous offrir la meilleure expérience utilisateur possible sur notre site Web. Les informations contenues dans les fichiers témoins sont stockées dans votre navigateur. Elles servent entre autres à vous reconnaître lorsque vous revenez sur notre site Web et à nous aider à déterminer quelles sections du site vous intéressent le plus ou vous sont les plus utiles. Pour en savoir davantage sur les informations que nous recueillons, veuillez consulter notre Politique de confidentialité . Strictly Necessary Cookies / Témoins strictement nécessaires Strictly Necessary Cookies should be enabled at all times so that we can save your preferences for cookie settings. Les témoins strictement nécessaires doivent être activés en tout temps pour que vos préférences concernant les paramètres des témoins puissent être enregistrées. Enable or Disable Cookies Enabled Disabled 3rd Party Cookies / Témoins tiers This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website. Ce site Web utilise Google Analytics pour collecter des informations anonymes telles que le nombre de visiteurs sur le site et les pages les plus populaires. En maintenant ces témoins activés, vous nous aidez à améliorer notre site Web. Enable or Disable Cookies Enabled Disabled Enable All / Activer tout Reject All / Refuser tout Save Changes / Enregistrer les modifications

The release as fetched from its publisher. ventustx.com ↗